Sheets Smith Investment Management’s Capricor Therapeutics CAPR Stock Holding History

Sheets Smith Investment Management’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$107K	Buy	+14,862	New	+$109K	0.07%	131

Other funds holding CAPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Sheets Smith Investment Management's CAPR Position: Q3 2025 in Review

Sheets Smith Investment Management opened a new position in Capricor Therapeutics (CAPR) in Q3 2025: 14,862 shares worth $107K. The stake represents 0.07% of the portfolio and ranks #131 among its holdings.

115 funds tracked by Wall St. Rank hold CAPR as of Q3 2025.

Sheets Smith Investment Management held 14,862 shares of Capricor Therapeutics worth $107K as of Q3 2025.
Capricor Therapeutics was a new Sheets Smith Investment Management position in Q3 2025.
Capricor Therapeutics made up 0.07% of Sheets Smith Investment Management's portfolio in Q3 2025, its #131 holding.
115 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2025.

Based on Sheets Smith Investment Management's 13F filing for Q3 2025, filed 8 Oct 2025.